🇺🇸 FDA
Patent

US 10813917

Treatment methods utilizing stem cell mobilizers and immunosuppressive agents

granted A61KA61K31/00A61K31/365

Quick answer

US patent 10813917 (Treatment methods utilizing stem cell mobilizers and immunosuppressive agents) held by MedRegen, LLC expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
MedRegen, LLC
Grant date
Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/00, A61K31/365, A61K31/395, A61K31/436